CLEC-2: the inside story. Blood 2015 Jun 25;125(26):3972-4
Date
06/27/2015Pubmed ID
26113533Pubmed Central ID
PMC4481588DOI
10.1182/blood-2015-04-636233Scopus ID
2-s2.0-84933567256 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
In this issue of Blood, Lorenz et al elucidate the mechanisms by which antibody-mediated targeting of platelet C-type lectinlike receptor 2 (CLEC-2) induces receptor downregulation and thrombocytopenia. This information is important because antibody-mediated targeting of CLEC-2 may have therapeutic utility as antithrombotic therapy, especially if thrombocytopenia can be avoided.
Author List
Newman DKAuthors
Debra K. Newman PhD Investigator in the Blood Research Institute department at BloodCenter of WisconsinDebra K. Newman PhD Professor in the Pharmacology and Toxicology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AnimalsBlood Platelets
Lectins, C-Type
Male
Platelet Activation